@timmermanreport
timmermanreport.com The AI Moment in Drug Discovery: Daphne Koller on The Long Run - TimmermanReport.com Daphne Koller is today’s guest on The Long Run. Daphne is the founder and CEO of South San Francisco-based Insitro. It’s one of what you could call the first-generation companies that uses AI to... 
timmermanreport.com Creating PROTACs and RIPTACs: Tim Shannon on The Long Run - TimmermanReport.com Tim Shannon is today’s guest on The Long Run. Tim is a general partner at Canaan Partners. He was a pulmonary and critical care physician in the early part of his career, before moving over to R&D... 
timmermanreport.com Touch, Pain, and the Edge of Neuroscience: Ardem Patapoutian on The Long Run - TimmermanReport.com Ardem Patapoutian is today’s guest on The Long Run. Ardem is a professor of neuroscience at Scripps Research in San Diego, and an investigator with Howard Hughes Medical Institute. His lab is focused... timmermanreport.com Long-Lasting Antibodies for Immune Diseases: Cameron Turtle on The Long Run - TimmermanReport.com Cameron Turtle is today’s guest on The Long Run. Cameron is the CEO of Waltham, Mass.-based Spyre Therapeutics. The company is developing antibody drug candidates that are engineered to be longer-l... timmermanreport.com Drugs That Go Where None Could Before: Mathai Mammen on The Long Run - TimmermanReport.com Mathai Mammen is today’s guest on The Long Run. Mathai is the CEO of Cambridge, Mass.-based Parabilis Medicines. The company has a platform for making drugs that hit elusive biological targets known... 